Funding round
Resilience Series D
Resilience, which works in biologics manufacturing in Blue Ash, raised $625M in a Series D round announced on 6 Jun 2022. It is Resilience's third venture round on record; the one before was a Series C in Aug 2021.
$625M
Amount raised
Not disclosed
Post-money valuation
Valuation
What this round says about the price
Resilience did not disclose a valuation in this round. It came 10 months after Resilience's Series C. It is 31% of the $2.02B Resilience has raised in the venture rounds on record. No later venture round is on record for Resilience.
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, geographic expansion, scaling operations and acquisitions.
- Product development
- Geographic expansion
- Scaling operations
- Acquisitions
Comparable rounds
How it compares
12 Series D rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $75M, and this round was 8.3 times the median. The closest in time, other companies' Series D rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 11 Jul 2022 | $50M | not disclosed | Sands Capital and Vivo Capital |
| Pharmaceutical Products | 14 Apr 2022 | $50M | not disclosed | not named |
| Pharmaceutical Products | 13 Sep 2022 | $160M | not disclosed | Viking Global and Sofinnova Partners |
| Pharmaceutical Products | 12 Sep 2022 | $43M | not disclosed | Knott Partners |
| Pharmaceutical Products | 1 Dec 2022 | $35M | not disclosed | Pfizer |
| Pharmaceutical Products | 2 Nov 2021 | $31M | not disclosed | Adjuvant Capital |
| Pharmaceutical Products | 21 Oct 2021 | $50M | not disclosed | 国寿大健康基金 and Centurium Capital |
| Rakuten Medical Pharmaceutical Products | 2 Aug 2021 | $166M | not disclosed | General Catalyst |
Sources
Where this comes from
Reported by 5 sources.
Questions
Frequently asked
How much did Resilience raise in its Series D round?
Resilience raised $625M in its Series D round, announced in Jun 2022.
What was Resilience's valuation at the Series D round?
It was not disclosed.
How does it compare with other Series D rounds in Pharmaceutical Products?
12 Series D rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $75M, and this round was 8.3 times the median.